Business Wire

Lipella’s Liposome Formulation of Botulinum Toxin (LP-09) Superior to Placebo for Overactive Bladder Symptoms in Double-Blind Trial

PITTSBURGH--(BUSINESS WIRE)--Pittsburgh based Lipella Pharmaceuticals Inc. today announced newly published results of a multi-site, double-blind, placebo-controlled clinical trial comparing the ...
Yahoo Finance

Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis

PITTSBURGH, April 03, 2024 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: “LIPO”) (“Lipella,” “our,” “us” or the “Company”), a clinical ...
Yahoo Finance

Lipella Pharmaceuticals Granted FDA Approval for Expanded Access Program for LP-310 in Oral Lichen Planus

PITTSBURGH, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing innovative ...
Pharmabiz

Lipella Pharma receives US FDA nod for expanded access programme for LP-310, an oral rinse formulation to treat oral lichen planus

Lipella Pharmaceuticals Inc, a clinical-stage biotechnology company focused on developing innovative therapies by reformulating active agents in existing generic drugs, announced that the US Food and ...